Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15296575 | 0.75 | IDO1 (0.39) | IDO1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL21025471 | 0.74 | IDO1 (0.36) | IDO1KDM4E | |
| SCHEMBL22607314 | 0.74 | IDO1 (0.31) | IDO1 | |
| SCHEMBL26247375 | 0.73 | NPC1 (0.41) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL24984454 | 0.73 | IDO1 (0.33) | IDO1 | |
| SCHEMBL9934402 | 0.71 | IDO1 (0.39) | IDO1 | |
| SCHEMBL12223303 | 0.70 | DRD2 (0.47) | KDM4EALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL21362935 | 0.70 | IDO1 (0.36) | IDO1 | |
| SCHEMBL4485534 | 0.70 | IDO1 (0.36) | IDO1 | |
| SCHEMBL18777238 | 0.67 | ALDH1A1 (0.36) | KDM4EALDH1A1POLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20190282703-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282703-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND USES THEREOF | ENPP1, ENPP3, ENPEP | IDO1 2399/4885KDM4E 3935/4885ALDH1A1 3097/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | IDO1 1653/4885KDM4E 3060/4885ALDH1A1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.